Drug Profile
Anti-CD4 CAR T-cell therapy - iCell Gene Therapeutics
Alternative Names: CD4 CAR-T cell therapy- iCell Gene TherapeuticsLatest Information Update: 11 Mar 2024
Price :
$50
*
At a glance
- Originator iCell Gene Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Chronic myelomonocytic leukaemia
- No development reported Peripheral T-cell lymphoma; Sezary syndrome
Most Recent Events
- 21 Feb 2024 Phase-I clinical trials in Chronic myelomonocytic leukaemia (Second-line therapy or greater, Recurrent) in USA (IV) (NCT06071624)
- 06 Oct 2023 iCell Gene Therapeutics plans a phase I trial for Chronic myeloid leukaemia (Second-line therapy or greater) in USA (IV, Infusion) (NCT06071624)
- 28 Jan 2023 No recent reports of development identified for phase-I development in Sezary-syndrome(Second-line therapy or greater) in USA (Parenteral, Infusion)